Germany · Delayed Price · Currency is EUR CompuGroup Medical SE & Co. KGaA Earnings Call Transcripts
Fiscal Year 2025
-
Q1 2025 saw modest revenue growth of 1% year over year, driven by recurring revenues, while one-time revenues declined. Adjusted EBITDA and EPS fell, but free cash flow improved significantly. Strategic partnership with CVC Capital Partners was finalized, and full-year guidance for low to mid-single-digit organic growth was confirmed.
Fiscal Year 2024
-
2024 saw a strategic shift with new leadership, key acquisitions, and a focus on innovation and recurring revenues. Organic revenue declined 2% year-over-year, but recurring revenues grew 5% and now make up nearly 75% of total revenues. Guidance for 2025 anticipates low- to mid-single digit organic growth and improved free cash flow.
-
An investment agreement with CVC Capital Partners includes a voluntary public tender offer at EUR 22 per share, a 51% premium, with plans to delist and retain family ownership. The partnership aims to drive innovation and growth, pending regulatory approvals and a minimum acceptance threshold.
-
Q3 2024 saw stable overall revenues as 6% growth in recurring revenues offset lower one-time revenues from project delays. Adjusted EBITDA and margins declined due to continued R&D investment, while free cash flow improved sequentially but remained below last year. Guidance for 2024 was revised downward, with a focus on operational excellence and innovation.
-
H1 2024 revenues fell 6% year-over-year, prompting a downward revision of 2024 guidance for revenue, EBITDA, free cash flow, and EPS. Delays in regulatory projects and increased AI investments drove the cut, but recurring revenues remain strong and management expects improvement in H2.